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Abstract
Based on our prior antitumor hits, 32 novel N-alkyl-N-substituted phenylpyridin-2-amine
derivatives were designed, synthesized and evaluated for cytotoxic activity against A549, KB,
KBVIN, and DU145 human tumor cell lines (HTCL). Subsequently, three new leads (6a, 7g, and
8c) with submicromolar GI50 values of 0.19 to 0.41 μM in the cellular assays were discovered,
and these compounds also significantly inhibited tubulin assembly (IC50 1.4–1.7 μM) and
competitively inhibited colchicine binding to tubulin with effects similar to those of the clinical
candidate CA-4 in the same assays. These promising results indicate that these tertiary
diarylamine derivatives represent a novel class of tubulin polymerization inhibitors targeting the
colchicine binding site and showing significant anti-proliferative activity.
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Introduction
Microtubules are formed by polymerization of heterodimers of α- and β-tubulin, and play
important roles in cellular activities, including cell structure maintenance, intracellular
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transport, mitosis, and cell division. Taxoids and vincristine alkaloids are two well-known
classes of anticancer drugs that act as tubulin inhibitors by targeting two distinct binding
sites (i.e., taxol and vinca sites) on the α,β-tubulin heterodimer1,2 and disrupting the
dynamics of microtubule assembly and disassembly. They are effective in the clinical
treatment of cancers, but do have certain deficiencies, including narrow therapeutic indexes
and emergence of drug resistance. In efforts to overcome these drawbacks, many new
tubulin inhibitors, which are targeted at the colchicine site, a third distinct binding site on
tubulin, have been discovered recently and are the subjects of intense investigation. Figure 1
shows examples of such inhibitors, including plant natural products and derivatives, as well
as synthetic small molecules. Because of their synthetic accessibility and structural diversity,
certain small molecule drug candidates. such as CA-4, ABT-751, and MPC-6827, are
currently undergoing clinical trials for treating cancers. These results greatly encourage
further efforts to design and discover novel small molecules that function as tubulin
polymerization inhibitors targeted at the colchicine binding site.
In our prior studies, we discovered two synthetic hits 6-chloro-N-(4-methoxyphenyl)- 3-
nitropyridin-2-amine (1a) and 6-chloro-2-(4-methoxyphenoxy)-3-nitro pyridine (1b) by
using cell assay screening. They showed promising cytotoxic activity (GI50 values 2.40–
13.5 μM and 1.18–2.03 μM, respectively) against a panel of human tumor cell lines
(HTCL), including A549, KB, KBVIN, and DU145.3 While the only structural difference
between 1a and 1b is the linker (NH or O) between the two aryl rings (A and B rings), 1b
was two- to seven-fold more potent than 1a. Therefore, we postulated that the linker might
be associated with the molecular antitumor potency. By performing a conformation analysis
using a molecular mechanics (MM2) method with energy minimization and dynamics
calculation,4 we found that the phenyl and pyridine rings of compounds 1a and 1b have
quite different spatial orientations as shown in Figure 2. Compound 1a has a conjugated
resonance system and a planar conformation, in which an intramolecular hydrogen bond
between the hydrogen of the NH linker and an oxygen atom of the ortho-nitrogen group
orients the phenyl and pyridine rings (A and B rings) in the same plane. The presence of the
intramolecular H-bond was validated by a down-field signal (δ 10.17 ppm) for the NH
proton in the 1H NMR spectrum of 1a. In contrast, the conformation of 1b shows a torsional
angle of 54.14° [C1-N2-C3-C4] between the two aryl rings, caused by electronic repulsion
between lone-pair electrons of the linker oxygen and the negatively charged ortho-nitro
group. Therefore, we hypothesize that a non-planar molecular conformation might be
favorable for enhancing antitumor potency. Even though 1a is less active than 1b, the NH
linker of 1a is modifiable and steric hindrance can be introduced to promote a non-planar
molecular conformation. Consequently, 6-chloro-N-(4-methoxyphenyl)-N-methyl-3-
nitropyridin-2-amine (3a), a tertiary amine derivative of 1a, was designed and synthesized.
In another positive design direction, 3a contains a 4-methoxy-N-methylanilino moiety as
also found in MPC-6827. Compound 3a exhibited significant cytotoxic activity against a
panel of human tumor cell lines with low micromolar GI50 values of 1.55 to 2.20 μM.
Accordingly, additional tertiary diarylamine derivatives 3–8 were designed, synthesized, and
evaluated for antitumor activity. The new target compounds are shown in the general
formula in Figure 2. The impact of substituents [R1 on the B-ring, R2 on the linker (Y), R3
and R4 on the A-ring] on the cytotoxic activity was investigated successively. Furthermore,
new active leads with high potency were tested in anti-tubulin assays to identify a potential
biological target and possible binding site. Our new results on the tertiary diarylamines,
including chemical synthesis, cytotoxicity against human tumor cells, SAR results, and
identification of biological target, are presented herein.
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As shown in Scheme 1, the designed target compounds 3–7 could be synthesized from
substituted 2-chloropyridines (2) and various commercially available anilines. Most of the
compounds were prepared by a coupling reaction between 2 and a substituted aniline in t-
BuOH in the presence of potassium carbonate either at room temperature for 12–24 h5
(method A for 3a, 3e, 3f) or under microwave irradiation at 120–160 °C for 10–30 min
(method B for 3c, 3d).6,7 As an exception, the coupling of 2,6-dichloro-3-nitropyridine (2a)
with N-methyl 4-cyanoaniline was carried out by direct heating under solvent-free
conditions to provide 3b in 37% yield. Consistent with our previous results,8 the
nucleophilic N-substituted aniline preferred to attack the 2,6-dichloropyridine (2)at the 2-
chloro position, which is ortho to an electron-withdrawing substituent R3 (such as NO2,
COOMe, and COOEt in 2a, 2c, and 2e, respectively) to produce corresponding series 3–7
compounds. However, when 3-cyano-2,6-dichloropyridine (2d) was treated with N-
methyl-4-methoxyaniline, 2- (7a) and 6-anilino products were formed in a 1:2 ratio,
indicating that the presence of the cyano (CN), a weak electron-withdrawing group, led to
less selectivity between the two chlorinated ortho- and para-positions on the pyridine ring.
By using the same aromatic nucleophilic substitution reaction, compounds 4a, 4b, 5a, 6a,
7a, and 7b were prepared from the appropriate chloropyridines 2a–e and N-substituted 4-
methoxyanilines. Acetylation of hit 1a with acetic anhydride in the presence of a catalytic
amount of concentrated sulfuric acid provided compound 4c. The 6-chloro in 3a and 6a was
converted to a methoxy or methylamine group by treatment with sodium methoxide or
methylamine in dry MeOH to produce corresponding compounds 5b, 6b or 5c, 6c,
respectively. Hydrolysis of 6a under basic conditions gave the carboxylic acid compound
7c, which was esterified with 2-iodopropane in acetone to produce 7d. The treatment of 7c
with 1-hydroxybenzotriazole (HOBt) in the presence of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDCI) hydrochloride salt, followed by the reaction with methylamine (30%
in MeOH) gave 7e, with 3-CONHMe (R3) on the pyridine ring, in moderate yield.9
Additionally, the ester group in 6a was reduced by reaction with lithium borohydride
(LiBH4) to give 3-hydroxymethyl compound 7f, which was converted to 3-methoxymethyl
compound 7g by treatment with iodomethane in the presence of sodium hydride in
anhydrous DMF.
Scheme 2 shows the synthesis of 6-trifluoromethylpyridine compounds 8c–l from 3-
substituted N-(4-methoxyphenyl)-6-trifluoromethylpyridin-2-amine 8a (R3 = COOMe) or
8b (R3 = CN), which were prepared by literature methods.10 Methylation of 8a and 8b with
methyl iodide in the presence of sodium hydride in DMF at low temperature (0 °C)
produced tertiary amines 8c and 8j, respectively. Hydrolysis, aminolysis, or reduction of the
ester group in 8c produced corresponding benzoic acid (8d), N-methyl carboxamide (8g),
and hydroxymethyl (8h) compounds, respectively. Further esterification of 8d with
iodoethane or 2-iodopropane in refluxing acetone gave ethyl ester 8e and isopropyl ester 8f,
respectively. Similarly to the preparation of 7g, methylation of 8h afforded methoxymethyl
compound 8i. A tetrazolyl ring (R3) was formed11 from the cyano group in 8j by treatment
with sodium azide and triethylamine hydrochloride in refluxing toluene to afford 8k.
However, this reaction did not go to completion, and ca. one-third of the starting 8j was
recovered, even after 36 h. Furthermore, methylation of 8k with dimethyl sulfate produced
the corresponding 8l. All target compounds were identified by 1H NMR and MS
spectroscopic data, and purity was determined by HPLC.
Results and discussion
The 32 newly synthesized tertiary diarylamines (series 3–8) were first evaluated for
cytotoxic activity using a HTCL panel, including A549 (lung carcinoma), DU145 (prostate
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cancer), KB (epidermoid carcinoma of the nasopharynx), and KBVIN (vincristine-resistant
KB), with paclitaxel as a reference compound. The in vitro anticancer activity (GI50) was
determined using the established sulforhodamine B (SRB) method.12 The cytotoxicity data
of all new tertiary amines in HTCL assays are listed in Tables 1 and 2. Some of the designed
tertiary diarylamine compounds were more potent than hit 1a (GI50 values 2.40–13.5) in the
HTCL assays. As shown in Table 1, compounds 3a with a para-methoxy (R1=OMe) and 3d
with a para-ester (R1=COOMe) on the phenyl ring displayed low micromolar GI50 values
ranging from 1.55 to 3.00 μM, and thus, were more potent than 3b with a para-cyano (21–27
μM) and 3e with 3,4-dimethoxy (15–18 μM) against the HTCL panel. However,
corresponding compounds 3c and 3f with 4-trifluoromethoxy or 3,4,5-trimethoxy
substitution, respectively, on the phenyl ring completely lost cytotoxic activity. These results
indicated that a para-substituent on the phenyl ring could enhance the antiproliferative
activity and a methoxy group was preferred to other substituents or multi-substituents on the
phenyl ring. Consequently, in the series 4 compounds, the 4-methoxyphenyl moiety was
retained, while the R2 group on the linker was varied. In comparison with 3a (R2 = Me, GI50
1.55–2.20 μM), compound 4a with a N-allyl group showed comparable potency, but a bulky
N-cyclopentyl group or an electron-withdrawing N-acetyl group resulted in significantly
reduced or no potency (see 4b and 4c). Thus, as we expected, a small alkyl group on the
linker might favor enhanced cytotoxic activity.
Next, we turned to modifications of the R3 and R4 substituents on the pyridine ring (A ring)
(see Table 2). The R4 on the pyridine ring was changed to methyl, methoxy, or N-
methylamine, rather than the chlorine atom in 3a. This change resulted in active compounds
5a–5c with GI50 values of 2.70–9.63 μM. Then, because a nitro group is generally
considered to be a moiety associated with risk and, thus, unacceptable in pharmaceutical
agents,13 compounds 6a–6c with a methoxy carbonyl (R3) rather than the nitro group in the
series 5 compounds and various R4 groups (Cl, OMe, and NHMe, respectively) on the A-
ring were synthesized and evaluated against the HTCL panel. Compound 6a exhibited sub-
micromolar GI50 values (0.20–0.26 μM) and was ten-fold more potent than 3a and 5a–c
(GI50 1.55–9.63 μM), 6b displayed similar potency to 5b, while 6c showed ten-fold higher
potency against KBVIN cell growth (GI50 0.92 μM) compared with 5c (GI50 9.63 μM). The
results from series 6 indicated that the R3 on the pyridine ring can be modified to enhance
potency and might have a greater impact on the potency than R4. Furthermore, two
additional compound series, 7 (a–g) and 8 (c–l) with a chloro or trifluoromethyl R4 group,
respectively, were synthesized in parallel to investigate the impact of various R3 groups on
the antiproliferative activity. Among them, 3-methyl or -ethyl ester pyridine compounds 7b,
8c, and 8e (R3 = COOMe or COOEt) showed high potency with low to sub-micromolar
GI50 values (0.19–1.81 μM) similar to series 6, regardless of whether R4 was chloro or
trifluoromethyl. In contrast, the presence of a 3-cyano (7a and 8j), 3-isopropyl ester (7d and
8f), 3-carboxylic acid (7c and 8d), or 3-methylamide (8g and 7e) on the pyridine ring
resulted in substantially reduced (GI50 >7.21μM) or no cytotoxic activity. Therefore, while a
methyl or ethyl ester R3 group was beneficial, a bulky (isopropyl ester) or negatively
charged (such as carboxylic acid at physiological pH) R3 substituent impaired the cytotoxic
activity. Interestingly, we observed that 3-methoxymethylpyridines 7g and 8i (R3 =
CH2OMe) and 3-hydroxymethylpyridines 7f and 8h (R3 = CH2OH) also were potent with
GI50 values of 0.20–3.25 μM, generally comparable with 3-methyl and -ethyl ester
compounds. Notably, compounds 6a (R3=COOMe, R4=Cl), 7g (R3= CH2OMe, R4=Cl), and
8c (R3=COOMe, R4=CF3) exhibited GI50 values between 0.19 and 0.41 μM against all four
HTCL. Similarly to 7c and 8d, compound 8k with a 3-tetrazole ring, a bio-isostere of a
carboxylic acid, on the pyridine ring was inactive. However, with a methylated tetrazole that
cannot ionize, compound 8l exhibited high potency with low micromolar GI50 values
ranging from 1.16 to 1.82 μM against the HTCL panel.
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More interestingly, we found that most active compounds in the series of tertiary
diarylamine showed equal or slightly better potency against both the KB and paclitaxel-
resistant KBVIN cell lines (see Tables 1 and 2). In contrast, paclitaxel showed nanomolar
activity against KB cells (GI50 8 nM), but significantly lower potency (GI50 1800 nM)
against the KBVIN cell line, which over-expresses P-glycoprotein, a drug efflux transporter.
These results indicated that these types of active compounds are not substrates of P-
glycoprotein and can overcome paclitaxel-resistance, providing a therapeutic advantage over
paclitaxel.
In investigating possible biological target(s), the three most active compounds 6a, 7g, and 8c
(GI50 0.19–0.41 μM) were tested in tubulin assays. As shown in Table 3, they showed high
activity for inhibition of tubulin assembly, with IC50 values ranging from 1.4 to 1.7 μM,
which are comparable to those with CA-4 (IC50 1.2 μM), a tubulin inhibitor currently in
phase II clinical trials, in the same assay. Furthermore, they inhibited the binding of
colchicine to tubulin (≥80%). These results suggest that these active diarylamines might
exert their effects by inhibiting tubulin polymerization targeted at the colchicine binding
site.
To better understand how the diarylamine analogues interact with tubulin, we investigated
the binding mode of 6a at the colchicine binding domain in the tubulin dimer by using
CDOCKER in the Discovery Studio 3.0 software. We attempted to dock 6a into two
different crystal structures, the tubulin/TN16 complex (PDB ID code: 3HKD) and the
tubulin/DMDA-colchicine complex (PDB ID code: 1SA0). We selected the former crystal
structure as our modeling system, because 6a showed a lower binding energy (−14.50 kcal/
mol) in 3HKD than in 1SA0 (−9.74 kcal/mol) and superposed very well with the native
ligand TN16 in the 3HKD structure. Figure 3A illustrates the binding mode of 6a (orange)
with tubulin protein and its overlap with TN16 (cyan). The methoxy group on the B-ring of
6a formed two hydrogen bonds with the carboxyl group of Glu200 and the hydroxyl of
Tyr202 in β-S6, while TN-16 formed one H-bond also with Glu200 and another H-bond
with Val238 in β-H7. The pyridine moiety (A-ring) of 6a bound in the lipophilic pocket
formed by the side chains of amino acids in β-S8 and β-H7, and the ester group on the A-
ring showed two hydrogen bonds with the side chain of Cys241, a key amino acid in the
colchicine binding site. For comparison, we superposed 6a, DMDA-colchicine (the native
ligand of 1SA0), and CA-4 into the same docking model, as shown in Figure 3B. While the
TN16 binding site extended deeply into the β-subunit side and less into the α-subunit,14,15
DMDA-colchicine (green) and CA-4 (blue) bound at the interface between the α- and β-
subunits of the tubulin dimer, and showed an overlap only with the pyridine ring of 6a. The
3,4,5-trimethoxyphenyl moieties found in both DMDA-colchicine and CA-4 overlapped
well and also formed H-bonds with the thiol group of Cys241, which plays a locating role
for most tubulin inhibitors binding at the colchicine binding site. The theoretical model of 6a
supports our bioassay results and can explain, at least partially, the high potency of 6a and
the preference for the ester group on the pyridine ring. Meanwhile, it also reveals obvious
differences in the binding conformations and orientations between our active compounds
and CA-4 in the colchicine binding site.
In summary, three new leads 6a, 7g, and 8c exhibited promising cytotoxic activity in human
tumor cell line assays with submicromolar GI50 values, significant potency against tubulin
assembly, and inhibitory activity for colchicine binding to tubulin protein. Notably, the
active tertiary diarylamine compounds showed high potency against paclitaxel-resistant
KBVIN cell lines, providing a potential advantage over paclitaxel. In addition, molecular
modeling studies revealed that the active 6a and CA-4 might have different binding modes.
Therefore, our active tertiary diarylamines might be a novel class of tubulin inhibitors
targeting the colchicine binding site. Current SAR studies on several series of N-methyl-N-
Wang et al. Page 5













(4-methoxyphenyl)pyridin-2-amines revealed the following conclusions: 1) a tertiary amine
linker is crucial for enhanced antitumor activity, and a methyl group is better than others, 2)
a para-methoxyphenyl moiety is favorable for antitumor activity, 3) the R3 group on the
pyridine ring can be modified to improve potency, and methyl ester and methoxymethyl
groups are better than other groups tested, 4) the R4 substituent on the pyridine ring also
contributes to the cytotoxic activity, but seems to have less impact than R3. We will use
these initial promising results to guide our further optimization of new compounds as tubulin
inhibitors targeting the colchicine binding site. In addition, because various tubulin
inhibitors targeting the colchicine binding site have been reported to selectively disrupt the
cytoskeleton of proliferating endothelial cells as vascular disrupting agents (VDAs),16, 17
further studies on our newly discovered active compounds will be necessary to develop a




The nuclear magnetic resonance (1H and 13C NMR) spectra were measured on a JNM-
ECA-400 (400 MHz and 100 MHz, respectively) spectrometer using tetramethylsilane
(TMS) as internal standard. The solvent used was CDCl3 unless otherwise indicated. Mass
spectra (MS) were measured on API-150 mass spectrometer with the electrospray ionization
source from ABI, Inc. Melting points were measured with a RY-1 melting apparatus without
correction. The microwave reactions were performed on a microwave reactor from Biotage,
Inc. Medium- pressure column chromatography was performed using a CombiFlash®
Companion system from ISCO, Inc. Thin-layer chromatography (TLC) was performed on
silica gel GF254 plates. Silica gel GF254 and H (200–300 mesh) from Qingdao Haiyang
Chemical Company were used for TLC, preparative TLC (PTLC), and column
chromatography, respectively. All commercial chemical reagents were purchased from
Beijing Chemical Works or Sigma-Aldrich, Inc. Purities of target compounds were
determined by using an Agilent HPLC-1200 with UV detector and an Agilent Eclipse XDB-
C18 column (150 mm × 4.6 mm, 5 μm) eluting with a mixture of solvents A and B
(acetonitrile/water 80:20), flow rate 0.8 mL/min and UV detection at 254 nm.
6-Chloro-N-(4-cyanophenyl)-N-methyl-3-nitropyridin-2-amine (3b)—A mixture of
2,6-dichloro-3-nitropyridine (2a, 94 mg, 0.5 mmol) and N-methyl 4-cyanoaniline (80 mg,
0.6 mmol) was heated neat at 120 °C under N2 protection for 4 h with stirring. Then the
mixture was diluted with CH2Cl2 and purified by preparative TLC (CH2Cl2/petroleum ether/
MeOH = 1/1.5/0.04) to obtain 40 mg of 3b in 37% yield, together with recovery of 24 mg of
2a, yellow solid, mp 98–100 °C; 1H NMR δ ppm 3.66 (3H, s, NCH3), 7.02 (1H, d, J = 8.4
Hz, PyH-5), 7.09 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.58 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.07
(1H, d, J = 8.4 Hz, PyH-4); MS m/z (%) 289 (M+1, 100), 291 (M+3, 35); HPLC purity
97.7%.
General procedure for coupling of substituted 2-chloropyridine and N-alkylaniline. Method
A (traditional)
A mixture of a substituted 2-chloropyridine (2, 1.0 mmol), N-methyl-4-methoxyaniline (1.5
mmol), and anhydrous potassium carbonate (2 mmol) in t-BuOH was stirred at rt for 12–24
h monitored by TLC until the reaction was complete. The mixture was poured into ice-
water, the pH adjusted to ca. 3.0 with aq HCl (2N), and the resulting solution extracted with
CH2Cl2 three times. The combined organic phases were washed with water and brine,
successively, until neutral and dried over anhydrous Na2SO4 overnight. After removal of
solvent in vacuo, the crude product was purified by flash column chromatography (gradient
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elution: EtOAc/petroleum ether, 0–50%) to obtain corresponding pure product. Method B
(microwave irradiation): A mixture of 2 (1.0 mmol), substituted aniline (1.5 mmol), and
anhydrous potassium carbonate (414 mg, 3.0 mmol) in 3 mL of t-BuOH was heated at 120–
160 °C with microwave-assistance for 10–30 min with stirring. The reaction mixture was
then poured into ice-water, pH adjusted to ~3.0 with aq HCl (2N), and solid crude product
was filtered. The product was then purified by the same methods as in Method A above.
6-Chloro-N-(4-methoxyphenyl)-N-methyl-3-nitropyridine-2-amine (3a)—Method
A. Starting with 193 mg of 2a and 206 mg of N-methyl 4-methoxyanaline to produce 240
mg of 3a, 82% yield, orange solid recrystallized from MeOH, mp 96–97 °C; 1H NMR δ
ppm 3.54 (3H, s, NCH3), 3.78 (3H, s, OCH3), 6.76 (1H, d, J = 8.4 Hz, PyH-5), 6.83 (2H, d, J
= 9.2 Hz, ArH-2′,6′), 7.00 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.88 (1H, d, J = 8.4 Hz, PyH-4);
MS m/z (%) 294 (M+1, 100), 296 (M+3, 32); HPLC purity 99.5%.
6-Chloro-N-methyl-3-nitro-N-(4-trifluoromethoxyphenyl)pyridin-2-amine (3c)—
Method B. Starting with 193 mg of 2a and 288 mg of N-methyl-4-trifluoro methoxyaniline
at 120 °C for 30 min to produce 198 mg of 3c, 57% yield, yellow liquid. 1H NMR δ ppm
3.59 (1H, s, NCH3), 6.87 (1H, d, J = 8.4 Hz, PyH-5), 7.08 (2H, d, J = 8.8 Hz, ArH-2′,6′),
7.16 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.96 (1H, d, J = 8.4 Hz, PyH-4); MS m/z (%) 348 (M
+1, 100), 350 (M+3, 25); HPLC purity 97.2%.
6-Chloro-N-methyl-N-(4-methoxycarbonylphenyl)-3-nitropyridin-2-amine (3d)—
Method B. Starting with 193 mg of 2a and 248 mg of methyl N-methyl-4-amino benzoate at
160 °C for 15 min to produce130 mg of 3d, 41% yield, brown solid, mp 106–107 °C; 1H
NMR δ ppm 3.67 (1H, s, NCH3), 3.89 (1H, s, OCH3), 6.94 (1H, d, J = 8.4 Hz, PyH-5), 7.07
(2H, d, J = 9.2 Hz, ArH-2′,6′), 7.98 (2H, d, J = 9.2 Hz, ArH-3′,5′), 8.02 (1H, d, J = 8.4 Hz,
PyH-4); MS m/z (%) 322 (M+1, 100), 324 (M+3, 28); HPLC purity 97.2%.
6-Chloro-N-(3,4-dimethoxyphenyl)-N-methyl-3-nitropyridin-2-amine (3e)—
Method A. Starting with 193 mg of 2a and 250 mg of N-methyl-3,4-dimethoxyaniline to
produce 262 mg of 3e, 81% yield, red solid, mp 145–146 °C; 1H NMR δ ppm 3.56 (s, 3H,
NCH3), 3.83 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 6.60 (2H, m, ArH-2′ and 6′), 6.78 (1H, d,
J = 8.0 Hz, PyH-5), 6.80 (1H, d, J = 9.2 Hz, ArH-4′), 7.88 (1H, d, J = 8.0 Hz, PyH-4); MS
m/z (%), 324.3 (M+1, 18), 325.9 (M+3, 6), 290.1 (M-33, 100); HPLC purity 99.2%.
6-Chloro-N-methyl-3-nitro-N-(3,4,5-trimethoxyphenyl)pyridin-2-amine (3f)—
Method A. Starting with 193 mg of 2a and 250 mg of N-methyl-3,4,5-trimethoxyaniline to
produce 268 mg of 3f, 76% yield, orange solid, mp 138–140 °C; 1H NMR δ ppm 3.60 (3H,
s, NCH3), 3.79 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.83 (3H, s, OCH3), 6.26 (2H, s,
ArH-2′,6′), 6.82 (1H, d, J = 8.4 Hz, PyH-5), 7.91 (1H, d, J = 8.4 Hz, PyH-4); MS m/z (%)
324.3 (M+1, 18), 325.9 (M+3, 6), 290.1 (M-33, 100); HPLC purity 99.5%.
N-Allyl-6-chloro-N-(4-methoxyphenyl)-3-nitropyridin-2-amine (4a)—Method B.
Starting with 193 mg of 2a and 244 mg of N-allyl-4-methoxyaniline at 120 °C for 10 min to
produce 168 mg of 4a, 53% yield, red liquid. 1H NMR δ ppm 3.77 (3H, s, OCH3), 4.63 (2H,
d, J = 5.6 Hz, NCH2), 5.16 and 5.18 (each 1H, dd, J = 17.6 Hz and 1.2Hz, CH2=), 5.99 (1H,
m, CH), 6.76 (1H, d, J = 8.4 Hz, PyH-5), 6.81 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.98 (2H, d, J
= 9.2 Hz, ArH-3′,5′), 7.87 (1H, d, J = 8.4 Hz, PyH-4); MS m/z (%) 320 (M+1, 100), 322 (M
+3, 25); HPLC purity 99.4%.
6-Chloro-N-cyclopentyl-N-(4-methoxyphenyl)-3-nitropyridin-2-amine (4b)—
Method B. Starting with 194 mg of 2a and 288 mg of N-cyclopentyl-N-4-methoxyaniline at
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160 °C for 20 min to produce 196 mg of 4b, 50% yield, yellow solid, mp 93–94 °C; 1H
NMR δ ppm 1.49-1.61 (6H, m, CH2 × 3), 2.02 (2H, m, CH2), 3.79 (1H, s, OCH3), 4.93 (1H,
m, CH), 6.70 (1H, d, J = 8.0 Hz, PyH-5), 6.83 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.93 (2H, d, J
= 9.2 Hz, ArH-3′,5′), 7.69 (1H, d, J = 8.0 Hz, PyH-4); MS m/z (%) 348 (M+1, 100), 350 (M
+3, 32); HPLC purity 98.7%.
N-(4-Methoxyphenyl)-N-methyl-6-methyl-3-nitropyridin-2-amine (5a)—Method B.
Starting with 174 mg of 2b and 206 mg of N-methyl-4-methoxyaniline at 140 °C for 20 min
to produce 154 mg of 5a, 56% yield, yellow solid, mp 97–98 °C; 1H NMR δ ppm 2.53 (3H,
s, CH3), 3.53 (3H, s, NCH3), 3.77 (3H, s, OCH3), 6.64 (1H, d, J = 8.0 Hz, PyH-5), 6.82 (2H,
d, J = 9.2 Hz, ArH-2′,6′), 6.99 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.86 (1H, d, J = 8.0 Hz,
PyH-4); MS m/z (%) 274 (M+1, 100); HPLC purity 98.5%.
Methyl 6-chloro-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinate (6a)—
Method B. Starting with 206 mg of methyl 2,6-dichloronicotinate (2c) and 206 mg of N-
methyl-4-methoxyaniline at 160 °C for 30 min to produce 186 mg of 6a, 60% yield, pale
yellow solid, mp 79–81 °C; 1H NMR δ ppm 3.28 (3H, s, NCH3), 3.47 (3H, s, OCH3), 3.78
(3H, s, OCH3), 6.74 (1H, d, J = 8.0 Hz, PyH-5), 6.84 (2H, d, J = 9.2 Hz, ArH-2′,6′), 7.02
(2H, d, J = 9.2 Hz, ArH-3′,5′), 7.61 (1H, d, J = 8.0 Hz, PyH-4); 13C NMR δ ppm 41.23,
51.79, 55.57, 113.21, 114.07, 114.74, 115.45, 125.55, 128.34, 141.30, 141.72, 151.33,
156.81, 156.98, 167.35; MS m/z (%) 307 (M+1, 100), 309 (M+3, 29); HPLC purity 99.2%.
6-Chloro-3-cyano-N-(4-methoxyphenyl)-N-methylpyridin-2-amine (7a)—Method
B. Starting with 173 mg of 3-cyano-2,6-dichloropyridine (2e) and 205 mg of N-methyl-4-
methoxyaniline at 160 °C for 15 min to produce 32 mg of 7a, 12% yield, white solid, mp
137–138 °C; 1HNMR δ ppm 3.47 (3H, s, NCH3), 3.85 (3H, s, OCH3), 6.18 (1H, d, J = 8.4
Hz, PyH-5), 6.99 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.14 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.38
(1H, d, J = 8.4 Hz, PyH-4). MS m/z (%): 274 (M+1, 100), 276 (M+3, 31); HPLC purity
99.0%.
Ethyl 6-chloro-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinate (7b)—Method
B. Starting with 220 mg of ethyl 2,6-dichloronicotinate (2d) and 205 mg of N-methyl-4-
methoxyaniline at 160 °C for 30 min to produce 173 mg of 7b, 54% yield, yellow solid, mp
79–81 °C; 1H NMR δ ppm 1.08 (3H, t, J = 7.6 Hz, CH3), 3.47 (3H, s, NCH3), 3.70 (2H, q, J
= 7.2 Hz, CH2), 3.78 (3H, s, OCH3), 6.73 (2H, d, J = 8.0 Hz, PyH-5), 6.83 (2H, d, J = 9.2
Hz, ArH-2′,6′), 7.03 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.61 (1H, d, J = 8.0 Hz, PyH-4); MS
m/z (%) 321.3 (M+1, 58), 323.3 (M+3, 20), 275.1 (M-45, 100); HPLC purity 96.7%.
6-Chloro-N-(4-methoxyphenyl)-N-methylcarbonyl-3-nitropyridin-2-amine (4c)—
To a solution of 2a (280 mg, 1.0 mmol) in Ac2O (8 mL) was added a drop of concentrated
H2SO4. The mixture was heated at 100 °C under N2 protection for 18 h with stirring. After
the reaction was completed, the mixture was poured into ice-water and neutralized with 5%
aq. NaOH. The collected solid was further purified by flash chromatography [gradient
eluant: EtOAc/petroleum ether, 0–50%] to obtain 249 mg of pure 4c, 77% yield, yellow
solid, mp 146–147 °C; 1H NMR δ ppm 2.01 (3H, s, CH3), 3.86 (3H, s, OCH3), 6.99 (2H, d,
J = 8.8 Hz, ArH-2′,6′), 7.31 (1H, d, J = 8.4 Hz, PyH-5), 7.49 (2H, d, J = 8.8 Hz, ArH-3′,
5′), 8.22 (1H, d, J = 8.4 Hz, PyH-4); MS m/z (%) 322 (M+1, 100), 324 (M+3, 28); HPLC
purity 97.8%.
6-Methoxy-N-(4-methoxyphenyl)-N-methyl-3-nitropyridin-2-amine (5b)—A
mixture of 3a (117 mg, 0.4 mmol) and NaOMe (ca. 1.0 mmol) in 3 mL of MeOH was
refluxed for 2 h with stirring. After the reaction was finished, the mixture was poured into
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ice-water to obtain 108 mg of pure 5b as a yellow solid, 93% yield, mp 56–57 °C; 1H NMR
δ ppm 3.54 (3H, s, NCH3), 3.78 (3H, s, OCH3), 3.99 (3H, s, OCH3), 6.19 ( 1H, d, J = 8.8
Hz, PyH-5), 6.83 (2H, d, J = 9.2 Hz, ArH-2′,6′), 7.02 (2H, d, J = 9.2 Hz, ArH-3′,5′), 8.03
(1H, d, J = 8.8 Hz, PyH-4); MS m/z (%) 290 (M+1, 100); HPLC purity 95.6%.
Methyl 6-methoxy-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinate (6b)—
Prepared in the same manner as for 5b. Starting with 123 mg of 6a to obtain119 mg of 6b in
98% yield, white solid, mp 78–80 °C; 1H NMR δ ppm 3.28 (3H, s, NCH3), 3.48 (3H, s,
OCH3), 3.78 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6.18 (1H, d, J = 8.4 Hz, PyH-5), 6.83 (2H,
d, J = 9.2 Hz, ArH-2′,6′), 7.03 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.71 (1H, d, J = 8.4 Hz,
PyH-4). MS m/z (%)303 (M+1, 24), 271 (M-31, 100); HPLC purity 97.9%.
N2,N6-Dimethyl-N-(4-methoxyphenyl)-3-nitropyridin-2,6-diamine (5c)—
Compound 3a (117 mg, 0.2 mmol) in 3 mL of 30% methylamine-MeOH solution was
refluxed for 12 h with stirring. After the reaction was completed, the mixture was poured
into ice-water, and the resulting red solid was collected to give 86 mg of pure 5c, 75% yield,
mp 169–170 °C; 1H NMR δ ppm 3.03 (3H, d, J = 5.2 Hz, NCH3), 3.49 (3H, s, NCH3), 3.76
(3H, s, OCH3), 5.01 (1H, bs, NH), 5.87 (1H, d, J = 9.2 Hz, PyH-5), 6.81 (2H, d, J = 8.8 Hz,
ArH-2′,6′), 7.02 (2H, d, J = 8.8 Hz, ArH-3′,5′), 8.00 (1H, d, J = 9.2 Hz, PyH-4); MS m/z
(%) 289 (M+1,27), 255 (M-33, 100); HPLC purity 100.0%.
Methyl 2-[N-(4-methoxyphenyl)-N-methyl)]amino-6-methylaminonicotinate (6c)
—Prepared in the same manner as for 5c. Starting with 123 mg of 6a to obtain 96 mg of 6c,
80% yield, white solid, mp 88–90 °C; 1H NMR δ ppm 2.97 (3H, d, J = 5.2 Hz, NHCH3),
3.28 (3H, s, NCH3), 3.43 (3H, s, OCH3), 3.76 (3H, s, OCH3), 4.69 (1H, bs, NH), 5.88 (1H,
d, J = 8.8 Hz, PyH-5), 6.80 (2H, d, J = 9.2 Hz, ArH-2′,6′), 7.01 (2H, d, J = 9.2 Hz, ArH-3′,
5′), 7.67 (1H, d, J = 8.8 Hz, PyH-4); MS m/z (%) 302 (M+1, 1), 227 (M-7, 100); HPLC
purity 100.0 %.
6-Chloro-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinic acid (7c)—To a
solution of 6a (154 mg, 0.5 mmol) in THF/MeOH (1.5 mL/1.5 mL) was added 3N aq NaOH
(3.0 mL) dropwise with stirring at rt for 36 h. The mixture was poured into 20 mL of water.
After removal of insoluble substance, the water phase was acidified with aq. HCl (2N) to pH
2. The precipitated solid was collected, washed with water, and dried to give 112 mg of pure
7c, 77% yield, yellow solid, mp 138–140 °C; 1H NMR δ ppm 3.43 (3H, s, OCH3), 3.72 (3H,
s, OCH3), 6.81 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.90 (1H, d, J = 8.0 Hz, PyH-5), 7.00 (2H, d,
J = 8.8 Hz, ArH-3′,5′), 7.90 (1H, d, J = 8.0 Hz, PyH-4). MS m/z (%) 293.2 (M+1, 100),
295.3 (M+3, 45); HPLC purity 95.2%.
Isopropyl 6-chloro-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinate (7d)—A
mixture of 7c (59 mg, 0.2 mmol), i-PrI (68 mg, 0.4 mmol), and K2CO3 (55 mg, 0.4 mmol) in
5 mL of acetone was refluxed for 4 h. K2CO3 was filtered out, and acetone was removed
under reduced pressure. The solid residue was purified by flash column chromatography
(gradient eluant: EtOAc/petroleum ether, 0–40%) to give 55 mg of pure 7d, 82% yield, pale
yellow solid, mp 56–58 °C; 1H NMR δ ppm 1.02 (6H, d, J = 6.0 Hz, CH3×2), 3.46 (3H, s,
NCH3), 3.76 (3H, s, OCH3), 4.60 (1H, m, CH), 6.73 (1H, d, J = 8.0 Hz, PyH-5), 6.82 (2H, d,
J = 9.2 Hz, ArH-2′,6′), 7.02 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.59 (1H, d, J = 8.0 Hz,
PyH-4); MS m/z (%) 335.4 (M+1, 32), 337.3 (M+3, 11), 275.1 (M-59+, 100); HPLC purity
95.5%.
N-Methyl 6-chloro-2-(N-(4-methoxyphenyl)-N-methyl)aminonicotinamide (7e)—
A mixture of 7c (84 mg, 0.29 mmol), EDCI (86 mg, 0.45 mmol) and HOBt (61 mg, 0.45
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mmol) in CH2Cl2 (4 mL) was stirred at rt for 30 min, and then 30% methyl amine (0.18
mL)-MeOH solution was added dropwise at 0 °C with stirring over 15 min, followed by
warming to to rt for an additional 90 min. After adding water (20 mL), the product was
extracted with CH2Cl2 three times. The combined organic phase was washed with water and
brine, successively, and dried over anhydrous Na2SO4 overnight. After removal of solvent
in vacuo, crude product was purified by flash column chromatography (gradient eluant:
EtOAc/petroleum ether, 0–50%) to give 59 mg of pure 7e, 66% yield, white solid, mp 150–
152 °C; 1H NMR δ ppm 2.52 (3H, d, J = 7.2 Hz, NHCH3), 3.39 (3H, s, NCH3), 3.77 (3H, s,
OCH3), 6.16 (1H, br, NH), 6.83 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.90 (1H, d, J = 7.6 Hz,
PyH-5), 6.95 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.74 (1H, d, J = 7.6 Hz, PyH-4); MS m/z (%)
306 (M+1, 16), 308 (M+3, 6), 275.1 (M-30, 100); HPLC purity 98.3%.
6-Chloro-3-hydroxymethyl-N-(4-methoxyphenyl)-N-methylpyridin-2-amine (7f)
—To a solution of 6a (123 mg, 0.4 mmol) in 5 mL of anhydrous THF, Light (88 mg, 4.0
mmol) was added at 0 °C with stirring over 15 min, and then the solution was warmed to rt
for 30 min. MeOH (0.5 mL) was then added dropwise to the mixture with stirring for an
additional 30 min. The mixture was poured into ice-water and extracted with EtOAc three
times. Combined organic phase was washed successively with water and brine, and dried
over anhydrous Na2SO4 overnight. After removal of solvent in vacuo, the crude product was
purified by flash column chromatography (gradient eluant: EtOAc/petroleum ether, 0–50%)
to to produce 91 mg of pure 7f, 82% yield, yellow oil. 1H NMR δ ppm 3.35 (3H, s, NCH3),
3.79 (3H, s, OCH3), 3.98 (2H, s, CH2), 6.84 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.92 (1H, d, J =
8.0 Hz, PyH-4), 6.95 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.60 (1H, d, J = 8.0 Hz, PyH-5); MS
m/z (%) 279.2 (M+1, 100), 281.2 (M+3, 34); HPLC purity 99.4%.
6-Chloro-3-methoxymethyl-N-(4-methoxyphenyl)-N-methylpyridin-2-amine (7g)
—To a solution of 7f (51 mg, 0.18 mmol) and MeI (0.03 mL, 0.54 mmol) in 6 mL of
anhydrous THF was added NaH (22 mg, 0.54 mmol, 60% oil suspension) at 0 °C and stirred
for 30 min at 0 °C and for 2 h at rt. The mixture was poured into ice-water and extracted
with EtOAc three times. The combined organic phase was washed with water and brine,
successively, and dried over anhydrous Na2SO4 overnight. After removal of solvent in
vacuo, the crude product was purified by flash column chromatography (gradient eluant:
EtOAc/petroleum ether, 0–30%) to give 41 mg of pure 7g, 78% yield, yellow oil. 1H NMR δ
ppm 3.15 (3H, s, OCH3), 3.36 (3H, s, NCH3), 3.69 (2H, s, OCH2), 3.79 (3H, s, OCH3), 6.82
(2H, d, J = 8.8 Hz, ArH-2′,6′), 6.91 (3H, m, PyH-5 and ArH-3′,5′), 7.58 (1H, d, J = 8.0 Hz,
PyH-4); 13C NMR δ ppm 42.07, 55.45, 58.29, 70.16, 114.59, 115.12, 116.09, 122.63,
125.09, 128.22, 138.86, 142.20, 147.50, 156.27, 157.05; MS m/z (%) 261 (M-31+, 100), 293
(M+1, 52), 295.3 (M+3, 18); HPLC purity 99.3%.
Methyl 2-(N-(4-methoxyphenyl)-N-methyl)amino-6-trifluoromethylnicotinate
(8c)—To a solution of methyl 6-chloro-2-[N-(4-methoxyphenyl)amino]-6-trifluoro-
methylnicotinate (8a, 120 mg, 0.37 mmol), and MeI (0.07 mL, 1.13 mmol) in DMF (3–5
mL) was added NaH (44 mg, 1.1 mmol, 60% oil suspension) at 0 °C with stirring for 1 h.
After the reaction was completed, the mixture was poured into ice-water and extracted with
EtOAc three times. The combined organic phase was washed with water and brine
successively, and dried over anhydrous Na2SO4 overnight. After removal of solvent in
vacuo, the crude product was purified by flash chromatography [gradient eluant: EtOAc/
petroleum ether, 0–50%] to produce 116 mg of 8c, 92% yield, yellow solid, mp 99–101
°C; 1H NMR δ ppm 3.30 (3H, s, NCH3), 3.50 (3H, s, OCH3), 3.79 (3H, s, OCH3), 6.85 (2H,
d, J = 9.2 Hz, ArH-2′,6′), 7.04 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.06 (1H, d, J = 8.0 Hz,
PyH-5), 7.74 (1H, d, J = 8.0 Hz, PyH-4); 13C NMR δ ppm 40.94, 51.83, 55.47, 109.46,
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114.66 (2C), 118.36, 125.78 (2C), 140.10, 140.92, 147.63, 147.97, 156.32, 157.05, 167.19;
MS m/z (%) 341 (M+1, 6), 309 (M-31, 100); HPLC purity 97.2%.
2-(N-(4-Methoxyphenyl)-N-methyl)amino-6-trifluoromethylnicotinic acid (8d)—
Prepared in a similar manner as for 7c. Starting with 170 mg of 8c to produce 118 mg of 8d,
72% yield, mp 146–148 °C; 1H NMR δ ppm 3.48 (3H, s, NCH3), 3.71 (3H, s, OCH3), 6.80
(2H, d, J = 8.8 Hz, ArH-2′,6′), 7.02 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.16 (1H, d, J = 7.6 Hz,
PyH-5), 7.95 (1H, d, J = 7.6 Hz, PyH-4); MS m/z (%) 261 (M−65−, 100), 325 (M−1−, 46);
HPLC purity 97.4%.
Ethyl 2-(N-(4-methoxyphenyl)-N-methyl)amino-6-trifluoromethylnicotinate (8e)
—Prepared in a similar manner as for 7d. Starting with 8d (163 mg, 0.5 mmol), EtI (153
mg, 1.0 mmol), and K2CO3 (138 mg, 1.0 mmol) to produce 156 mg of 8e, 88% yield, yellow
solid, mp 105–106 °C; 1H NMR δ ppm 1.09 (3H, t, J = 5.6 Hz, CH3), 3.50 (3H, s, NCH3),
3.70 (3H, q, J = 7.2 Hz, OCH2), 3.79 (3H, s, OCH3), 4.01 (2H, d, J = 5.6 Hz, CH2), 6.84
(2H, d, J = 9.2 Hz, ArH-2′,6′), 7.04 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.06 (1H, d, J = 7.6 Hz,
PyH-5), 7.74 (1H, d, J = 7.6 Hz, PyH-4). MS m/z (%)355.2 (M+1, 28), 309.3 (M-45, 100);
HPLC purity 100.0%.
Isopropyl 2-(N-(4-methoxyphenyl)-N-methyl)amino-6-trifluoromethylnicotinate
(8f)—Prepared in a similar manner as for 7d. Starting with 8d (42 mg, 0.13 mmol), i-PrI (66
mg, 0.39 mmol), and K2CO3 (54 mg, 0.39 mmol) to produce 45 mg of 8f, 94% yield, pale
yellow solid, mp 108–109 °C; 1H NMR δ ppm 1.04 (6H, d, J = 6.4 Hz, CH3×2), 3.49 (3H, s,
NCH3), 3.77 (3H, s, OCH3), 4.59 (1H, m, CH), 6.84 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.04
(2H, d, J = 8.8 Hz, ArH-3′,5′), 7.06 (1H, d, J = 7.6 Hz, PyH-5), 7.72 (1H, d, J = 7.6 Hz,
PyH-4). MS m/z (%) 369.3 (M+1, 8), 309.3 (M-59, 100); HPLC purity 96.5%.
N-Methyl 2-(N-(4-methoxyphenyl)-N-methyl)amino-6-trifluoromethyl
nicotinamide (8g)—A solution of 8c (49 mg, 0.14 mmol) in 3 mL of 30% methylamine-
MeOH solution was stirred at rt for 4 days. After removal of solvent in vacuo, the crude
product was purified with flash column chromatography (gradient eluant: EtOAc/petroleum
ether, 0–60%) to provide 35 mg of 8g, 74% yield, white solid, mp 151–152 °C; 1H NMR δ
ppm 2.51 (3H, d, J = 4.8 Hz, NHCH3), 3.42 (3H, s, NCH3), 3.78 (3H, s, OCH3), 6.00 (1H,
br, CONH), 6.84 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.98 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.20
(1H, J = 7.6 Hz, PyH-5), 7.84 (1H, J = 7.6 Hz, PyH-4); MS m/z (%) 340 (M+1, 4), 309 (M
−30, 100); HPLC purity 100.0%.
3-Hydroxymethyl-N-(4-methoxyphenyl)-N-methyl-6-trifluoromethylpyridin-2-
ami ne (8h)—Prepared in a similar manner as for 7f. Starting with 8c (136 mg, 0.4 mmol)
to produce 102 mg of 8h, 82% yield, yellow oil. 1H NMR δ ppm 3.38 (3H, s, NCH3), 3.80
(3H, s, OCH3), 4.01 (2H, d, J = 5.6 Hz, CH2), 6.84 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.96 (2H,
d, J = 9.2 Hz, ArH-3′,5′), 7.26 (1H, d, J = 7.6 Hz, PyH-5), 7.80 (1H, d, J = 7.6 Hz, PyH-4);
MS m/z (%) 312 (M+1, 100); HPLC purity 99.1%.
3-Methoxymethyl-N-(4-methoxyphenyl)-N-methyl-6-trifluoromethylpyridine-2-a
mine (8i)—Prepared in a similar manner as for 7g. Starting with 8h (110 mg, 0.35 mmol),
MeI (0.06 mL, 1.0 mmol), and NaH (40 mg, 1.0 mmol, 60% oil suspension) to produce 94
mg of 8i, 82% yield, yellow oil. 1H NMR δ ppm 3.17 (3H, s, OCH3), 3.39 (3H, s, NCH3),
3.72 (2H, s, OCH2), 3.80 (3H, s, OCH3), 6.83 (2H, d, J = 8.8 Hz, ArH-2′,6′), 6.94 (2H, d, J
= 8.8 Hz, ArH-3′,5′), 7.23 (1H, d, J = 7.6 Hz, PyH-5), 7.76 (1H, d, J = 7.6 Hz, PyH-4). MS
m/z (%) 327 (M+1, 27), 295 (M-31, 100); HPLC purity 99.6%.
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—The preparation, work-up, and purity are the same as for 8c. Starting with 3-cyano-N-(4-
methoxyphenyl)-6-trifluoromethylpyridin-2-amine (8b) (586 mg, 2.0 mmol), MeI (0.25 mL,
4.0 mmol), and NaH (160 mg, 60% oil suspension) in 3 ml of DMF at 0 °C with stirring for
1 hour to afford 565 mg of pure 8j, 92% yield, white solid, mp 83–84 °C; 1H NMR δ ppm
3.47 (3H, s, NCH3), 3.84 (3H, s, OCH3), 6.96 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.98 (1H, d, J
= 7.6 Hz, PyH-5), 7.20 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.77 (1H, d, J = 7.6 Hz, PyH-4); MS
m/z (%) 308 (M+1, 100); HPLC purity 97.6%.
N-(4-Methoxyphenyl)-N-methyl-3-(1H-tetrazol-5-yl)-6-trifluoromethylpyridin-2-
amine (8k)—To a solution of 8j (417 mg, 1.3 mmol) in toluene (5 mL) was added 4 drops
of water, NaN3 (266 mg, 4.1 mmol), and Et3N·HCl (562 mg, 4.1 mmol) successively. The
mixture was heated at reflux temperature for 36 h, After cooling to rt, the mixture was added
to saturated aq. Na2CO3 (5 mL) and water (5 mL), and then extracted with petroleum ether
three times. The organic phase was washed successively with water and brine, and dried
over MgSO4. After removal of petroleum ether in vacuo, 176 mg of unreacted 8c was
recovered from the organic phase. The water phase was acidified with aq. HCl (2N) to pH
2~3, filtered, and dried to give 262 mg of 8k, 95% yield, yellow solid, mp 225 °C
(decomposition); 1H NMR (DMSO-d6) δ ppm 3.36 (3H, s, NCH3), 3.62 (3H, s, OCH3), 6.63
(2H, d, J = 8.8 Hz, ArH-2′,6′), 6.82 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.47 (1H, d, J = 7.6 Hz,
PyH-5), 7.96 (1H, d, J = 7.6 Hz, PyH-4). MS m/z (%) 349 (M-1, 60), 278 (M-72, 100);
HPLC purity 95.5%.
N-(4-Methoxyphenyl)-N-methyl-3-(1-methyl-tetrazol-5-yl)-6-trifluoromethylpyrid
in-2-amine (8l)—A mixture of 8k (101 mg, 0.29 mmol), Me2SO4 (0.05 mL, 0.58 mmol),
and K2CO3 (80 mg, 0.58 mmol) in acetone (5 mL) was refluxed for 5 h. After cooling to rt,
additional acetone (ca. 10 mL) was added and solid K2CO3 was filtered out. After removal
of solvent in vacuo, the residue was purified with flash column chromatography (gradient
eluant: EtOAc/petroleum ether, 0–30%) to afford 55 mg of 8l, 52% yield, pale yellow solid,
mp 115–116 °C; 1H NMR δ ppm 3.51 (3H, s, NCH3), 3.69 (3H, s, NCH3), 4.08 (3H, s,
OCH3), 6.60 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.83 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.21 (1H,
d, J = 7.6 Hz, PyH-5), 7.83 (1H, d, J = 7.6 Hz, PyH-4); MS m/z (%) 365 (M+1, 3), 279
(M-85, 100); HPLC purity 100.0%.
Antiproliferative Activity Assay
Target compounds were assayed by SRB method for cytotoxic activity using the HTCL
assay according to procedures described previously.18,19,20 The panel of cell lines included
human lung carcinoma (A-549), epidermoid carcinoma of the nasopharynx (KB), P-gp-
expressing epidermoid carcinoma of the nasopharynx (KBVIN), and prostate cancer
(DU145). The cytotoxic effects of each compound were expressed as GI50 values, which
represent the molar drug concentrations required to cause 50% tumor cell growth inhibition.
Tubulin Assays
Tubulin assembly was measured by turbidimetry at 350 nm as described previously.21 Assay
mixtures contained 1.0 mg/mL (10 μM) tubulin and varying compound concentrations were
pre-incubated for 15 min at 30 °C without guanosine 5′-triphosphate (GTP). The samples
were placed on ice, and 0.4 mM GTP was added. Reaction mixtures were transferred to 0 °C
cuvettes, and turbidity development was followed for 20 min at 30 °C following a rapid
temperature jump. Compound concentrations that inhibited increase in turbidity by 50%
relative to a control sample were determined.
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Inhibition of the binding of [3H]colchicine to tubulin was measured as described
previously.22 Incubation of 1.0 μM tubulin with 5.0 μM [3H]colchicine and 5.0 μM
inhibitor was for 10 min at 37 °C, when about 40–60% of maximum colchicine binding
occurs in control samples.
Molecular Modeling Studies
All molecular modeling studies were performed with Discovery Studio 3.0 (Accelrys, San
Diego, USA). The crystal structures of tubulin in complex with TN16 (PDB: 3HKD) and
with DMDA-colchicine (PDB: 1SA0) were downloaded from the RCSB Protein Data Bank
(http://www.rcsb.org/pdb) for possible use in the modeling study. We selected the structure
3HKD as our modeling system, because of lower binding energy of 6a with it and matched
binding orientation between 6a and TN16. The CDOCKER was used to evaluate and predict
in silico binding free energy of the inhibitors and automated docking. The protein protocol
was prepared by several operations, including standardization of atom names, insertion of
missing atoms in residues and removal of alternate conformations, insertion of missing loop
regions based on SEQRES data, optimization of short and medium size loop regions with
Looper Algorithm, minimization of remaining loop regions, calculation of pK, and
protonation of the structure. The receptor model was typed with the CHARMm forcefield. A
binding sphere with radius of 9Å was defined through the native ligand as the binding site
for the study. The docking protocol employed total ligand flexibility and the final ligand
conformations were determined by the simulated annealing molecular dynamics search
method set to a variable number of trial runs. The docked ligands (6a, TN16, DMDA-
colchicine, and CA-4) were further refined using in situ ligand minimization with the Smart
Minimizer algorithm by the standard parameters. The ligand and its surrounding residues
within the above defined sphere were allowed to move freely during the minimization, while
the outer atoms were frozen. The implicit solvent model of Generalized Born with
Molecular Volume (GBMV) was also used to calculate the binding energies.
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Plant natural products, derivatives, and synthetic compounds as tubulin inhibitors targeted at
the colchicine binding site. Some of them are in clinical trials.
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A) Hits, design, and a general formula of new tertiary diarylamines. B) Preferred
conformations of 1a and 1b. The torsional angle C1—N2—C3—C4 is defined as positive if,
when viewed along the N2—C3 bond, atom C1 must be rotated clockwise to eclipse atom
C4.
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A) A predicted mode of compound 6a (orange stick model) binding with tubulin (PDB ID
code: 3HKD), and overlapping with TN16 (cyan stick model, the native ligand of 3HKD);
B) The superimposition of docked compound 6a with DMDA-colchicine (green stick model,
the native ligand of 1SA0) and CA-4 (blue stick model). Surrounding amino acid side chains
are shown in gray stick format and labeled. The hydrogen bonds are shown by green dashed
lines and the distance between the ligands and protein is less than 3 Å
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Synthesis of 3–7 series. a) neat, 140 °C, N2, 4 h for 3b; K2CO3/t-BuOH, r.t., 12–24 h or
microwave irradiation. 120–160 °C, 10–30 min for others; b) Ac2O/H2SO4, 90 °C, 18 h; c)
NaOMe/MeOH, reflux, 2 h; d) MeNH2/MeOH, reflux, 12 h; e) i. aq. NaOH (3N), THF/
MeOH, rt, 36 h; ii. HCl (2N); f) i-PrI, K2CO3, acetone, reflux, 4 h; g) LiBH4, THF, MeOH,
rt, 2 h; h) CH3I, NaH (60% oil suspension), THF, rt, 2 h; i) i. HOBt, EDCI, CH2Cl2, rt, 30
min; ii. NH2Me (30% in MeOH), 1.5 h, rt.
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Synthesis of 8 series. a) CH3I, NaH (60% oil suspension), DMF, 0 °C, 1 h; b) i. aq. NaOH
(3N), THF/MeOH, r.t, 36 h; ii. HCl (2N); c) EtI or i-PrI, K2CO3, acetone, reflux, 4 h; d)
NH2Me, MeOH, rt, 4 days; e) LiBH4, THF, MeOH, rt, 2 h; f) CH3I, NaH (60% oil
suspension), THF, rt, 2 h; g) NaN3, Et3N·HCl, toluene, reflux, 36 h; h) Me2SO4, K2CO3,
acetone, reflux, 5 h.
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Table 3
Inhibition of Tubulin Assemblya and Colchicine Bindingb
compound inhibition of tubulin assembly IC50 (μM) ± SD inhibition of colchicine binding (%) ± SD
6a 1.40 ± 0.01 80 ± 2.0
7g 1.50 ± 0.20 88 ± 0.5
8c 1.70 ± 0.20 82 ± 1.0
CA-4c 1.20 ± 0.20 98 ± 0.6
a
The tubulin assembly assay measured the extent of assembly of 10 μM tubulin after 20 min at 30 °C.
b
Tubulin: 1 μM. [3H]colchicine: 5 μM. Inhibitor: 5 μM. Incubation was performed for 10 min at 37 °C.
c
reference compound is a drug candidate in phase II clinical trial.
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